125 IMPLANT SEEDS, MODEL STM1251

K991280 · Sourcetech Medical, LLC · KXK · Oct 20, 1999 · Radiology

Device Facts

Record IDK991280
Device Name125 IMPLANT SEEDS, MODEL STM1251
ApplicantSourcetech Medical, LLC
Product CodeKXK · Radiology
Decision DateOct 20, 1999
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 892.5730
Device ClassClass 2
AttributesTherapeutic

Intended Use

I-125 Implant Seeds are indicated for permanent interstitial treatment of selected localized tumors such as head and neck, lung, pancreas and early stage prostate. I-125 Implant Seeds may be used in superficial, intraabdominal or intra-thoracic locations. I-125 Implant Seeds may also be used in the treatment of residual tumors following completion of external beam radiation therapy and for other recurrent tumors.

Device Story

I-125 Implant Seeds are radioactive brachytherapy sources used for permanent interstitial treatment of localized tumors. Seeds are implanted directly into tumor tissue, delivering localized radiation to destroy malignant cells while sparing surrounding healthy tissue. Used in clinical settings by physicians (e.g., radiation oncologists) for head, neck, lung, pancreatic, and prostate cancers. Device provides continuous low-dose-rate radiation therapy. Clinical benefit includes targeted tumor control for primary, residual, or recurrent malignancies.

Clinical Evidence

No clinical data provided; substantial equivalence based on technological characteristics and intended use.

Technological Characteristics

Radioactive I-125 (Iodine-125) seeds for interstitial brachytherapy. Form factor: small encapsulated seeds for permanent implantation. Energy source: radioactive isotope decay. No software or electronic components.

Indications for Use

Indicated for permanent interstitial brachytherapy of localized tumors, including head and neck, lung, pancreas, and early-stage prostate. Applicable for superficial, intra-abdominal, or intra-thoracic locations, and for residual or recurrent tumors following external beam radiation therapy.

Regulatory Classification

Identification

A radionuclide brachytherapy source is a device that consists of a radionuclide which may be enclosed in a sealed container made of gold, titanium, stainless steel, or platinum and intended for medical purposes to be placed onto a body surface or into a body cavity or tissue as a source of nuclear radiation for therapy.

Special Controls

*Classification.* Class II (special controls). A prostate seeding kit intended for use with a radionuclide brachytherapy source only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized image of an eagle with three stripes representing the agency's mission to promote health, well-being, and human services. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 OCT 20 1999 David T. Sieracki Quality Assurance Manager SourceTech Medical, L.L.C. 295 E. Lies Road Carol Stream, IL 60188 Re: K991280 I-125 Implant Seeds, STM 1251 Dated: August 10, 1999 Received: August 12, 1999 Regulatory class: II 21 CFR 892.5730/Procode: 90 KXK Dear Mr. Sieracki: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in requlatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, CAPT Daniel G. Schultz, M.D. Acting Director, Division of Reproductive, Abdominal. Ear. Nose and Throat. and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {1}------------------------------------------------ ## SECTION D: STATEMENT OF INDICATIONS FOR USE SourceTech Medical, L.L.C. Applicant: 510(k) Number: 1251mplant Seeds Device Name: 125 Implant Seeds are indicated for permanent interstitial treatment of Indications for use: selected localized tumors such as head and neck, lung, pancreas and early stage prostate. 123 mplant Seeds may be used in superficial, intraabdominal or intra-thoracic locations. 129 mplant Seeds may also be used in the treatment of residual tumors following completion of external beam radiation therapy and for other recurrent tumors. David C. Segura (Division Sign-Off) Division of Reproductive, Abdominal, ENT and Radiological Devic 510(k) Number Prescription Use (Per 21 CFR 801.109)
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%